GlaxoSmithKline shares rise on FDA approval of Breo Ellipta

GlaxoSmithKline's shares rose Thursday after the healthcare company announced US approval of Breo Ellipta, a treatment for chronic obstructive pulmonary disease (COPD).

GlaxoSmithKline's shares rose Thursday after the healthcare company announced US approval of Breo Ellipta, a treatment for chronic obstructive pulmonary disease (COPD).

Breo Ellipta, once-daily inhaled treatment for the long-term, maintenance treatment of airflow obstruction in patients with COPD, was given the green light from the Food and Drug Administration's (FDA) Pulmonary-Allergy Drugs Advisory Committee.

Advertisement - Article continues below

The committee voted that the efficacy and safety data provide substantial evidence to support approval of the medication. The company submitted a new drug application to the FDA for approval of Breo last July.

"We are pleased with the outcome of today's meeting," said President of GlaxoSmithKline Pharmaceuticals, Patrick Vallance.

"COPD is a debilitating and progressive disease. Its symptoms are often severe and can have a huge impact on patients' lives. This positive recommendation is a crucial first step towards making Breo Ellipta available for appropriate COPD patients across the US.

"We look forward to a final decision from the FDA later this year."




Investment strategy

Broker safety – your questions answered

Cris Sholto Heaton answers more of your questions about the safety of stockbroker accounts
25 Mar 2020
Investment strategy

How demographics affects stock valuations

New research suggests that stock and bond valuations are driven by the age of the population – at least in the US.
24 Feb 2020
Stocks and shares

Do you own shares in Sirius Minerals? Here’s what you need to do now

Mining giant Anglo American has proposed a cash takeover of Yorkshire-based minnow Sirius Minerals. Unhappy shareholders must decide whether to accept…
20 Feb 2020

Why investors should be “cautiously bullish” for 2020

Analysts have been out in force making rosy predictions for stockmarkets in 2020, but while there is certainly a case for optimism, investors should r…
17 Jan 2020

Most Popular

UK Economy

What bounce back loans can tell us about how we’ll pay for all this

The government will guarantee emergency "bounce back loans" for small businesses hit by Covid-19. Inevitably, many businesses will default. And there'…
1 Jun 2020

This looks like the biggest opportunity in today’s markets

With low interest rates and constant money-printing, most assets have become expensive. But one major asset class hasn’t. John Stepek explains why com…
2 Jun 2020
Global Economy

The MoneyWeek Podcast: James Ferguson on the virus, the lockdown, and what comes next

Merryn talks to MoneyWeek regular James Ferguson of Macrostrategy Partnership about what's happened so far with the virus; whether the lockdown was th…
28 May 2020